详情页 - 广东省中医院知识库

资源类型：

文章类型：

作者：

Gao, Hong-Fei[1,2,3,4,5,6,7,8] * ; Wu, Zhiyong[1,2,3,4,5,6,7,8] ; Lin, Ying[1,2,3,4,5,6,7,8]

; Song, Xiangyang[1,2,3,4,5,6,7,8] ; Cao, Yin[1,2,3,4,5,6,7,8] ; Liu, Zhenzhen[1,2,3,4,5,6,7,8]

; Chen, Qian-Jun[1,2,3,4,5,6,7,8]

; Zhang, Liulu[1,2,3,4,5,6,7,8] ; Yang, Ci-Qiu[1,2,3,4,5,6,7,8] ; Yang, Mei[1,2,3,4,5,6,7,8] ; Zhu, Teng[1,2,3,4,5,6,7,8] ; Li, Jieqing[1,2,3,4,5,6,7,8] ; Ji, Fei[1,2,3,4,5,6,7,8] ; Cheng, Min-Yi[1,2,3,4,5,6,7,8] ; Wang, Kun[1,2,3,4,5,6,7,8] ;

机构： [1]Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Canc, Dept Breast Canc, Guangzhou 510080, Peoples R China [2]Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China [3]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [4]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China [5]Dongguan Peoples Hosp, Dept Breast Surg, Dongguan, Peoples R China [6]Henan Tumor Hosp, Zhengzhou, Henan, Peoples R China [7]Tradit Chinese Med Hosp Guangdong Prov, Dept Breast Oncol, Guangzhou, Peoples R China [8]Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, Guangzhou, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2018]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Ctr Canc, Dept Breast Canc, Guangzhou 510080, Peoples R China [2]Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China [3]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [4]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China [5]Dongguan Peoples Hosp, Dept Breast Surg, Dongguan, Peoples R China [6]Henan Tumor Hosp, Zhengzhou, Henan, Peoples R China [7]Tradit Chinese Med Hosp Guangdong Prov, Dept Breast Oncol, Guangzhou, Peoples R China [8]Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, Guangzhou, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/trastuzumab) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial

文献详情